Nephros Reports First Quarter 2016 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nephros Reports First Quarter 2016 Financial Results

RIVER EDGE, NJ--(Marketwired - May 11, 2016) - Nephros, Inc. ( OTCQB : NEPH ), (the "Company") a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF") system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today financial results for the three months ended March 31, 2016.

"During the first quarter of 2016, we continued to focus on executing our strategy and achieving our operational goals," said Daron Evans, President and Chief Executive Officer of the Nephros. "We attained 510(k) clearance on two additional products and we successfully completed the software upgrade and additional training development for our H2H modules needed to expand our hemodiafiltration footprint. Moving forward in 2016, our primary goal is to achieve positive cash flow by the end of the year."

Recently Launched Products

The SSUmini, launched in March 2016, offers dialysis clinics with an economical solution to provide hemodialysis quality water as a polish filter for smaller, portable reverse osmosis ("RO") systems and to provide hemodialysis quality bicarbonate concentrate for dialysis clinics with centralized bicarbonate systems.

The S100, which received 510(k) clearance from the Food and Drug Administration (FDA) in April 2016, offers hospitals and medical facilities an end-of-faucet solution to protect patients from water-borne bacteria.

The AETHER® ultrafilter, launched in March 2016, offers the food service and hospitality industry protection from particulate contaminants larger than 0.005 microns, the smallest barrier currently available in the industry.

Upcoming Milestones by Product Line

EndoPur™

The Company filed for Special 510(k) clearance of its 10", 20", 30" and 40" endotoxin cartridge filters in April 2016. In May 2016, the FDA converted the application to a Traditional 510(k) filing. The Company filed a separate Special 510(k) for the 10" version of its EndoPur™ filter. The Company aims to launch the 10" filter size early in the third quarter of 2016, subject to completion of the FDA clearance process. Due to the longer FDA review process associated with a Traditional 510(k) submission, the Company aims to launch the 20", 30" and 40" filter sizes late in the third quarter or early in the fourth quarter of 2016, subject to completion of the FDA clearance process.

EndoPur™ will become the brand name for all of the Company's ultrafiltration products for dialysis water and bicarbonate concentrate, including the DSU-D, the SSU-D, the SSUmini and the 10" cartridge platform.

PathoGuard™

The Company recently filed for the "PathoGuard" trademark, which will become the brand name for its hospital infection prevention products which are designed to protect patients from water borne pathogens, including the DSU-H, the SSU-H, and the S100.

The Company intends to file for 510(k) clearance for the 10" cartridge platform to be used in hospitals and medical clinics as part of its goal to provide its distributors and customers with a broad portfolio of products to simplify installation.

NanoGuard™

The NanoGuard™ product line will become the brand name encompassing the Company's industrial and household products.

The Company is on track to ship its first 30 GPM systems at the beginning of the third quarter. The stainless steel flushable filter system is designed to remove submicron particulates in high-pressure, closed-loop water systems, including cooling systems for data centers and hot water return loops in commercial buildings. Initial data suggests the filters have ability to remove both organic and inorganic particulates.

In the third quarter, the Company intends to begin beta testing flushable versions of its 10" cartridge platform at selected sites, including private residences. A smaller, flushable system could be ideal for homes utilizing well-water, or in locations where boil-water warnings are frequent.

Financial Performance for the Quarter Ended March 31, 2016

Total revenues for the quarter ended March 31, 2016 were approximately $590,000, compared to approximately $544,000 for the year ended March 31, 2015. Total operating expenses for the quarter ended March 31, 2016 were approximately $1,101,000, compared to approximately $1,088,000 for the quarter ended March 31, 2015.

Net cash used in operating activities for the quarter ended March 31, 2016 was approximately $522,000, compared to $917,000 for the quarter ended March 31, 2015. As of March 31, 2016, Nephros had cash and cash equivalents of approximately $701,000.

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.

For more information about Nephros, please visit the company's website at www.nephros.com .

Forward-Looking Statements

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the EndoPur™, including its eligibility for Special 510(k) clearance and the timing of its commercial launch, the PathoGuard™, including the Company's plans to submit a 510(k) application for such product, the NanoGuard™, including the timing of planned testing, and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including potential delays in the regulatory approval process, changes in business, economic and competitive conditions, the availability of capital when needed, our dependence on third party manufacturers, regulatory reforms, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros Inc.'s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2015. Nephros, Inc. does not undertake any responsibility to update the forward-looking statements in this release.

   
NEPHROS, INC. AND SUBSIDIARY  
CONSOLIDATED BALANCE SHEETS  
(In Thousands, Except Share and Per Share Amounts)  
   
    (Unaudited)     (Audited)  
    March 31, 2016     December 31, 2015  
ASSETS                
Current assets:                
  Cash   $ 701     $ 1,248  
  Accounts receivable, net     569       397  
  Investment in lease, net - current portion     22       -  
  Inventory, net     476       591  
  Prepaid expenses and other current assets     105       228  
    Total current assets     1,873       2,464  
  Property and equipment, net     41       12  
  Investment in lease, net - less current portion     71       -  
  Other assets, net     1,442       1,494  
    Total assets   $ 3,427     $ 3,970  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY                
Current liabilities:                
  Accounts payable   $ 744     $ 652  
  Accrued expenses     290       237  
  Deferred revenue, current portion     70       70  
    Total current liabilities     1,104       959  
  Long-term portion of deferred revenue     330       347  
    Total liabilities     1,434       1,306  
                 
Commitments and Contingencies                
                 
Stockholders' equity:                
Preferred stock, $.001 par value; 5,000,000 shares authorized at March 31, 2016 and December 31, 2015; no shares issued and outstanding at March 31, 2016 and December 31, 2015     -       -  
Common stock, $.001 par value; 90,000,000 shares authorized at March 31, 2016 and December 31, 2015; 48,825,461 and 48,580,355 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively.     49       49  
Additional paid-in capital     119,961       119,797  
Accumulated other comprehensive income     72       71  
Accumulated deficit     (118,089 )     (117,253 )
Total stockholders' equity     1,993       2,664  
Total liabilities and stockholders' equity   $ 3,427     $ 3,970  
                 
                 
   
NEPHROS, INC. AND SUBSIDIARY  
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS  
(In Thousands, Except Share and Per Share Amounts)  
(Unaudited)  
   
    Three Months Ended March 31,  
    2016     2015  
Net revenues:                
Product revenues   $ 545     $ 527  
License and royalty revenues     45       17  
Total net revenues     590       544  
Cost of goods sold     295       262  
Gross margin     295       282  
Operating expenses:                
  Research and development     269       192  
  Depreciation and amortization     55       53  
  Selling, general and administrative     777       843  
Total operating expenses     1,101       1,088  
Loss from operations     (806 )     (806 )
Change in fair value of warrant liability     -       1,009  
Interest expense     (14 )     (11 )
Interest income     1       -  
Other income (expense)     (17 )     51  
Net income (loss)     (836 )     243  
Other comprehensive income, foreign currency translation adjustments     1       -  
Total comprehensive income (loss)   $ (835 )   $ 243  
Net income (loss) per common share, basic   $ (0.02 )   $ 0.01  
Weighted average common shares outstanding, basic     48,173,521       30,259,823  
Net loss per common share, diluted   $ (0.02 )   $ (0.02 )
Weighted average common shares outstanding, diluted     48,173,521       37,082,499  
                 

Contact: Investor: PCG Advisory Group Kirin M. Smith Chief Operating Officer Direct: 646-863-6519 www.pcgadvisory.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 111

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 170

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 103

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 55

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 161

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 139

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 89

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 61

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
Salvation Army’s Angel Tree: 2026 Holiday Cheer Drive

Updated Category News Views 120

Kickstarting Holiday Generosity: The Angel Tree Program Man, there's something heartwarming about a Christmas that shines bright for everyone. The Salvation Army's Angel Tree program is back for another season, rolling up with a mission to spark joy across the country. For over 45 years now, this initiative's been the answer to many Christmas wish lists, especially for...

Continue Reading

Top 5 Most Recently Viewed Articles

Gap Inc. Sees Minor Sales Growth Amid Market Challenges

Updated Category News Views 254

Gap Inc. Experiences Modest Growth Gap Inc. demonstrated resilience in a challenging market, achieving a 1% increase in net sales compared to the previous year. The comparable sales rose by 3%, reflecting the brand's enhancement strategies. Brand Performance Highlight Each of Gap Inc.'s four major brands—Old Navy, Gap, Banana Republic, and Athleta—gained market share,...

Continue Reading
Innovative Lock Design Enhances Security for Commercial Trailers

Updated Category News Views 761

The SMART LOC: A Game-Changer for Trucking Security In a world where cargo theft is a persistent challenge, the development of an innovative solution is essential. Enter the SMART LOC, a new locking mechanism designed specifically for commercial trailers. This invention aims to significantly enhance security for trucking professionals, ultimately providing much-needed...

Continue Reading
GXO Logistics Prepares for First Quarter Earnings Call Soon

Updated Category News Views 198

GXO Logistics Set for First Quarter Earnings Presentation GXO Logistics, Inc. (NYSE: GXO) is preparing for its first quarter earnings conference call, which is scheduled for May 8, 2025, at 8:30 a.m. Eastern Time. During this call, the company will share its financial results and key insights into its business performance. Interested participants are encouraged to join in...

Continue Reading
Legal Action Against Everus Construction Group for Investors

Updated Category News Views 132

Overview of Legal Proceedings Against Everus Construction Group Everus Construction Group, Inc. (NYSE: ECG) is currently facing significant legal challenges as a result of alleged securities law violations. The situation has prompted attention from shareholders and investors alike. The Gross Law Firm has taken the initiative to notify shareholders regarding this serious...

Continue Reading
Nxera Pharma and Cancer Research UK Collaborate to Combat Cancer

Updated Category News Views 121

Nxera Pharma Joins Forces with Cancer Research UK for Innovative Trials HTL0039732, a promising oral EP4 antagonist developed by Nxera, shows potential in tackling various types of cancer, especially when paired with leading immunotherapies. Currently, this drug is making progress through its Phase 1/2a clinical trials, highlighting its potential effectiveness across a...

Continue Reading